ArticlePloS one2026
National and subnational burden and attributable risk factors of osteoarthritis, rheumatoid arthritis, and low back pain in Iran: 1990-2019 findings of the Global Burden of Disease (GBD) Study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prevalence of chronic diseases has increased concurrent with the increase in life expectancy and musculoskeletal disorders (MSDs) are among them. They have a high burden all over the world and are among the leading causes of years lived with disability (YLDs). MSDs are generally divided into six categories, and osteoarthritis (OA), rheumatoid arthritis (RA), and low back pain (LBP) are among most of the most prevalent MSDs. In this study, we aimed to assess the burden of these three disorders in Iran.
methodsData were retrieved from the global burden of disease (GBD) study 2019 to investigate the epidemiological features of the burden of RA, OA, and LBP and the attributed burden to their risk factors in Iran and its provinces.
resultsThe total number of OA, RA, and LBP increased from 1990 to 2019. Although the age-standardized incidence rate (ASIR) of LBP decreased by -8.4%, the ASIR of OA and RA increased by 7.3% and 7.6% (reached 445.0 (95% uncertainty interval 395.9 to 501.9) and 5.0 (4.5 to 5.6) per 100,000 population in 2019, respectively). The age-standardized prevalence rate (ASPR) of OA and RA increased by 7.0% and 9.3%, respectively (5588.2 (5041.2 to 6228.6) and 109.1 (97.8 to 120.9) in 2019) while, the ASPR of LBP decreased by 9.5% (8,486.5 (7,533.8 to 9,528.3) in 2019). Females were more prone to establish OA and RA, but males were more predisposed to developing LBP. The highest OA incidence rate was presented in 55-59 years with a decreasing pattern over 59 years, 35-39 years with a decreasing pattern for older patients for RA, and 75-79 years with an increasing LBP incidence observed as age increased.
conclusionLBP, OA, and RA are still significant health issues, and the number of patients is increasing, which imposes much burden. The increase in the prevalence of MSDs in Iran alarmingly highlights the need for immediate policies designed to reduce their burden. Therefore, epidemiological information helps make policies and reallocate sources that can improve healthcare services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.